Jul 2026· Journal of clinical neuroscience· Vol 152, pp.
112187
· 0 citations· 14 references
Medicine
TL;DR
Willingness to undergo VNS again was associated with relative improvement and lower postoperative residual seizure burden, suggesting that residual seizure burden may provide complementary patient-centered information when interpreted alongside conventional response measures and established patient-reported outcomes.
Abstract
Objective
To assess whether postoperative residual seizure burden may provide patient-centered information beyond relative seizure improvement by examining willingness to undergo vagus nerve stimulation (VNS) again in drug-resistant epilepsy (DRE).
Methods
This single-center cross-sectional study included patients with DRE after VNS implantation. Baseline data were retrieved from an institutional database, and follow-up data were collected using a structured questionnaire. The primary outcome was willingness to undergo VNS again, treated as an exploratory decision-centered patient-reported measure and analyzed as yes versus no/uncertain. Subjective seizure improvement, quality-of-life (QoL) improvement, overall satisfaction, willingness to recommend VNS, and adverse effects were also assessed. Seizure burden before and after VNS was graded using broad frequency-based categories. Category improvement reflected relative improvement, whereas postoperative residual burden reflected the absolute burden remaining after treatment.
Results
Of 58 screened patients, 54 were included. Overall, 32/54 (59.3%) would undergo VNS again, 22/54 (40.7%) were satisfied, and 25/54 (46.3%) would recommend VNS. Subjective seizure improvement and QoL improvement were reported by 35/54 (64.8%) and 33/54 (61.1%) patients, respectively. Seizure burden category improved in 35/54 (64.8%), but 11/54 (20.4%) continued to have daily seizures after VNS. Patients willing to undergo VNS again were more likely than those unwilling or uncertain to report subjective seizure improvement (87.5% vs 31.8%, P < 0.001), QoL improvement (90.6% vs 18.2%, P < 0.001), and seizure burden category improvement (81.2% vs 40.9%, P = 0.004). They also had lower postoperative residual seizure burden (median category 1.0 [IQR 0.0-2.3] vs 3.0 [IQR 2.0-4.0], P < 0.001).
Conclusions
Willingness to undergo VNS again was associated with relative improvement and lower postoperative residual seizure burden. These findings suggest that residual seizure burden may provide complementary patient-centered information when interpreted alongside conventional response measures and established patient-reported outcomes.
Postoperative ASM reduction was associated with domain-specific cognitive improvement following ATL, particularly in WM, which support ASM tapering as a potentially modifiable factor influencing postoperative cognitive outcomes.
Kazushi Ukishiro, S. Osawa, M. Ogawa et al.· Epilepsia· 0 citations
Background: Disorders of consciousness (DoC) have limited effective therapies. Implantable vagus nerve stimulation (VNS) is established for epilepsy but remains underexplored for DoC with comorbid epilepsy. Objectives: To evaluate whether VNS is associated with improved consciousness recovery in DoC patients with epile...
J. Zuo, K. Ma, Zizhang Cheng et al.· Therapeutic Advances in Neur...· 0 citations
Palliative surgical procedures for pediatric DRE are safe and associated with seizure reduction, decreased medication burden, and gradual improvement in adaptive functioning and early surgical intervention may help minimize developmental decline and improve long-term adaptive outcomes.
Ana Valeria Duarte Oliveira, H. Machado, Ú. Thomé et al.· Child's Nervous System· 0 citations
A significant trend toward improved seizure outcomes and change in quality of life was observed with longer treatment durations, and no significant differences were observed in overall ASM load between baseline and any follow-up visit.
Abstract Background Major depressive disorder (MDD) is a leading cause of disability. Despite multiple treatment strategies, a substantial proportion of patients do not achieve adequate symptom relief. This subgroup is known as treatment-resistant depression (TRD) and poses clinical and challenges. Among them, individu...
Y. Domany, K. Feffer, I. Štraus et al.· International Journal of Neu...· 0 citations
Neuromodulation for drug-resistant epilepsy is associated with modest improvements in depression and quality of life without meaningful cognitive deterioration over follow-up durations of 6 months to 14 years.
Margil Ranpariya, Gurleen Kaur, H. Shallwani et al.· Acta Neurologica Belgica· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.